IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Price, Quote, News and Overview
NASDAQ:IPA - Nasdaq - CA45257F2008 - Common Stock - Currency: USD
IPA Quote, Performance and Key Statistics
0.3861
-0.02 (-4.22%)
The current stock price of IPA is 0.3861 USD. In the past month the price decreased by -35.65%. In the past year, price decreased by -79.68%.
IPA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
| DHR | DANAHER CORP | 28.07 | 151.18B | ||
| A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
| IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
| WAT | WATERS CORP | 31.58 | 22.26B | ||
| ICLR | ICON PLC | 14.39 | 16.63B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
| ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
| RVTY | REVVITY INC | 23.23 | 13.85B | ||
| AVTR | AVANTOR INC | 17.3 | 11.78B | ||
| TEM | TEMPUS AI INC | N/A | 10.72B |
Related stock screener links
About IPA
Company Profile
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Victoria, British Columbia. The firm owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. The company has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The firm utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Company Info
IMMUNOPRECISE ANTIBODIES LTD
3204-4464 Markham St.
Victoria BRITISH COLUMBIA CA
Employees: 87
Company Website: https://www.ipatherapeutics.com/
Investor Relations: https://www.immunoprecise.com/investors/
Phone: 16048060626
IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ
What is the stock price of IMMUNOPRECISE ANTIBODIES LTD today?
The current stock price of IPA is 0.3861 USD. The price decreased by -4.22% in the last trading session.
What is the ticker symbol for IMMUNOPRECISE ANTIBODIES LTD stock?
The exchange symbol of IMMUNOPRECISE ANTIBODIES LTD is IPA and it is listed on the Nasdaq exchange.
On which exchange is IPA stock listed?
IPA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNOPRECISE ANTIBODIES LTD stock?
6 analysts have analysed IPA and the average price target is 5.1 USD. This implies a price increase of 1220.9% is expected in the next year compared to the current price of 0.3861. Check the IMMUNOPRECISE ANTIBODIES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNOPRECISE ANTIBODIES LTD worth?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a market capitalization of 17.67M USD. This makes IPA a Nano Cap stock.
How many employees does IMMUNOPRECISE ANTIBODIES LTD have?
IMMUNOPRECISE ANTIBODIES LTD (IPA) currently has 87 employees.
What are the support and resistance levels for IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a resistance level at 0.42. Check the full technical report for a detailed analysis of IPA support and resistance levels.
Is IMMUNOPRECISE ANTIBODIES LTD (IPA) expected to grow?
The Revenue of IMMUNOPRECISE ANTIBODIES LTD (IPA) is expected to grow by 0.58% in the next year. Check the estimates tab for more information on the IPA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IPA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IPA, evaluating the profitability, health, valuation and growth aspects
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Chart to make your own analysis
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Latest news and press-releases to stay up to date.
Does IMMUNOPRECISE ANTIBODIES LTD (IPA) stock pay dividends?
IPA does not pay a dividend.
When does IMMUNOPRECISE ANTIBODIES LTD (IPA) report earnings?
IMMUNOPRECISE ANTIBODIES LTD (IPA) will report earnings on 2025-03-12, before the market open.
What is the Price/Earnings (PE) ratio of IMMUNOPRECISE ANTIBODIES LTD (IPA)?
IMMUNOPRECISE ANTIBODIES LTD (IPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.32).
What is the Short Interest ratio of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
The outstanding short interest for IMMUNOPRECISE ANTIBODIES LTD (IPA) is 0.83% of its float. Check the ownership tab for more information on the IPA short interest.
IPA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IPA. When comparing the yearly performance of all stocks, IPA is a bad performer in the overall market: 93.28% of all stocks are doing better.
IPA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IPA. IPA has a bad profitability rating. Also its financial health evaluation is rather negative.
IPA Financial Highlights
Over the last trailing twelve months IPA reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS increased by 28.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.92% | ||
| ROE | -84.27% | ||
| Debt/Equity | 0.45 |
IPA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to IPA. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 14.37% and a revenue growth 0.58% for IPA